1
Inpharma 1365 - 23 Nov 2002 Morphine-6-glucuronide * prevents postoperative pain as effectively as morphine, according to recently announced results of a phase II clinical trial. 68 patients undergoing hip replacement surgery received a single IV dose of either morphine-6-glucuronide 20 mg/70kg at the induction of general anaesthesia (n = 24), morphine-6-glucuronide 30 mg/70kg at the end of surgery (n = 20), or morphine 10 mg/70kg at the end of surgery. There were no significant between-group differences in postoperative pain, as assessed by the patient for 24 hours after the operation. Treatment with morphine-6-glucuronide, especially the higher dose, was associated with decreases in postoperative morphine consumption, nausea and retching/vomiting, compared with morphine. * CeNeS Pharmaceuticals; phase II for postoperative pain CeNeS Pharmaceuticals plc. CeNeS Announces Further Positive Results of its Phase II Clinical Trials of Morphine-6-glucuronide (M6G). Media Release : 15 Nov 2002. Available from: URL: http://www.cenes.co.uk 809015243 1 Inpharma 23 Nov 2002 No. 1365 1173-8324/10/1365-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Morphine-6-glucuronide equal to morphine for postoperative pain

  • View
    215

  • Download
    2

Embed Size (px)

Citation preview

Page 1: Morphine-6-glucuronide equal to morphine for postoperative pain

Inpharma 1365 - 23 Nov 2002

■ Morphine-6-glucuronide* prevents postoperativepain as effectively as morphine, according to recentlyannounced results of a phase II clinical trial. 68patients undergoing hip replacement surgery receiveda single IV dose of either morphine-6-glucuronide 20mg/70kg at the induction of general anaesthesia (n =24), morphine-6-glucuronide 30 mg/70kg at the end ofsurgery (n = 20), or morphine 10 mg/70kg at the endof surgery. There were no significant between-groupdifferences in postoperative pain, as assessed by thepatient for 24 hours after the operation. Treatmentwith morphine-6-glucuronide, especially the higherdose, was associated with decreases in postoperativemorphine consumption, nausea and retching/vomiting,compared with morphine.* CeNeS Pharmaceuticals; phase II for postoperative pain

CeNeS Pharmaceuticals plc. CeNeS Announces Further Positive Results of itsPhase II Clinical Trials of Morphine-6-glucuronide (M6G). Media Release : 15Nov 2002. Available from: URL: http://www.cenes.co.uk 809015243

1

Inpharma 23 Nov 2002 No. 13651173-8324/10/1365-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved